Genmab — Februar 2025
-
Not so fun fact: Der er udstedt 20mill aktier siden 2012 og det stopper ikke. Buyback sletter ikke aktier. https://www.macrotrends.net/stocks/charts/GNMSF/genmab/shares-outstanding
-
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 – Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed once-weekly prophylaxis treatment (regular treatment to prevent prolonged and spontaneous bleeding) with investig
Yahoo Finance (finance.yahoo.com)
-
i didn't realise they were this far in children already. Let's hope Novo can speed up the regulatory submission a bit. "At week 26, 98% of caregivers said they preferred Mim8 to prior treatment, of which 73% said they ‘very strongly’ preferred Mim8 to prior treatment."
-
Novo Nordisk adds pediatric data to bulging bag of evidence on near-approval hemophilia A prospect https://www.fiercebiotech.com/biotech/novo-adds-pediatric-data-bulging-bag-evidence-near-approval-hemophilia-prospect
-
"the prior treatment" being Hemlibra, or..?
-
Time for an upward adjustment of Mim8 peak sales estimates, perhaps?
-
Hvilke peak sales estimater har i set på Mim8?
-
Helimbra solgte i 2023 for 4,7 mia $. https://finance.yahoo.com/news/hemlibra-emicizumab-sales-increase-8-055300995.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAFN6KMaKixReHe__AJhRzQORzfQmBY-WjuR584ocJwn_q8Ibw3pEEAXgR9CvT0hp04-RxR8AZs3_pCGnH80yXz1CXP-Ks2q3SLlATyV70hIzx0xetat5zg_xLXwOXN7u2UvuhZERCY2AE0p2sRV99xUzMnf02tkTrXJfvRdCS7jz
-
Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB-002 in Von Willebrand Disease at the 2025 EAHAD Annual Congress https://hemab.com/#post-hemab-therapeutics-presents-interim-data-from-ongoing-phase-2-study-of-hmb-001-as-first-ever-prophylactic-treatment-in-glanzmann-thrombasthenia-and-preclinical-data-from-hmb-002-in-von-willebrand-dise
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind